RXO Inc (NYSE: RXO) has recently been the focus of various research firms. On February 9, 2026, Stephens set a price target of $15 for RXO. At that time, RXO's stock price was $16, which is 6.25% higher than the target. This indicates a potential downside according to Stephens' analysis.
The stock has received a consensus "Hold" rating from nineteen research firms, as highlighted by Marketbeat.com. Among these firms, four recommend selling, eleven suggest holding, and four advise buying. The average twelve-month target price is approximately $16.07, which aligns closely with the current stock price of $16.07.
Several firms have adjusted their price targets for RXO. Citigroup lowered its target from $16 to $15, maintaining a "neutral" rating. Truist Financial reduced its target from $20 to $18 but still recommends a "buy." UBS Group reiterated a "neutral" rating, while Zacks Research downgraded RXO to a "strong sell."
RXO's stock price has seen fluctuations, trading between $15.76 and $17.40 today. Over the past year, it reached a high of $22.17 and a low of $10.43. The company's market capitalization is approximately $2.64 billion, with a trading volume of 2,392,948 shares on the NYSE.
